Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.47 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | FABP1 | P07148 | 5/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.44 |
| ▸ | FEN1 | P39748 | 2/20 | 0.44 |
| ▸ | CASP3 | P42574 | 1/20 | 0.44 |
| ▸ | CASP7 | P55210 | 1/20 | 0.44 |
| ▸ | CASP6 | P55212 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28546624 | 0.88 | TSHR (0.55) | TSHRCYP3A4CYP2C9CYP2C19HCRTR1 | |
| SCHEMBL15924957 | 0.77 | TSHR (0.51) | TSHRCYP3A4CYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL3045649 | 0.75 | L3MBTL1 (0.62) | TSHRCYP2C9 | |
| SCHEMBL14009509 | 0.73 | TSHR (0.48) | TSHRCYP3A4CYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL4599905 | 0.73 | PKM (0.62) | TSHRCYP3A4CYP2C9CYP2C19 | |
| SCHEMBL27750067 | 0.73 | HCRTR1 (0.44) | TSHRCYP3A4CYP2C9CYP2C19HCRTR1 | |
| SCHEMBL29432508 | 0.72 | ALDH1A1 (0.73) | SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL5002963 | 0.72 | TSHR (0.47) | TSHRCYP3A4CYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL31681326 | 0.72 | ALDH1A1 (0.73) | TSHRCYP3A4CYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL17007454 | 0.72 | DHCR7 (0.55) | TSHRHCRTR1HCRTR2OPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6686355-B2 | TREATING HEART DISEASE, MULTIPLE SCLEROSIS, ARTHRITIS, ATHEROSCLEROSIS, AND OSTEOPOROSIS; ANTICANCER AGENTS | WARNER-LAMBERT COMPANY | 2004-02-03 | — | — | US | disclosed |
| US-20020156074-A1 | Biphenyl sulfonamides useful as matrix metalloproteinase inhibitors | BARVIAN NICOLE CHANTEL (US) | 2002-10-24 | — | — | US | disclosed |
| EP-1233016-A1 | Biphenyl sulfonamides useful as matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2002-08-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156074-A1 | Biphenyl sulfonamides useful as matrix metalloproteinase inhibitors | MMP3, MMP9, MMP13 | TSHR 1912/4885CYP3A4 975/4885CYP2C9 211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.